A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
← catalyst calendarNCT07772531 · readout in 810 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
200estimated
Sites
26
Countries
Czechia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-10-30 | estimated | When the study began enrolling |
| Primary completion | 2028-11-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-06 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Major Depressive Disorder
Interventions
- Drug: BMS-986511 — also filed as Evifacotrep
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFMean change from baseline in Hamilton Depression Rating Scale -17 Item (HDRS-17) total score
measured Up to Day 57
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed